Revlimid: Trends in Use (Wave 2)

Specialties:

Revlimid: Trends in Use (Wave 2)

A Survey of Fifty Hematologist/Oncologists & Oncologists

Study Description

Topic	Revlimid
Respondent Type	Physicians
Specialties Covered	Hematologist/Oncologists & Oncologists
Region	United States Only
Methodology	Online survey, self-administered via a Panel Intelligence website § 30-minute self-administered survey § Fielded online from February 22-26, 2007

Objectives

To track changes between Wave 1 and Wave 2 regarding the current and potential use of Revlimid. Specific objectives include:

§ Examine the current uses and impressions of Revlimid

§ Predict future use of Revlimid for different lines of treatment

§ Identify reasons for predicted changes in use of Revlimid in the future

§ Clarify side effects and cost issues that may play a role in the current and future use of Revlimid

Companies and Products Mentioned in This Report

Company	Ticker Symbol	Product(s)
Celgene Corporation	CELG	Revlimid

Inclusion Criteria and Respondent Demographics

Inclusion Criteria

§ Have been in practice between 2 and 30 years

§ Spend at least 75% of their professional time in clinical practice

§ Currently treating at least 10 Myelodysplastic Syndrome (MDS) patients and Multiple Myeloma (MM) patients combined

about us